OSE Pharma to attend BioPharm America

September 15th to 16th, 2015, Boston, United-States

Paris, September 14th 2015, 5:45 PM – OSE Pharma SA (ISIN: FR0012127173; Mnémo: OSE), a biotechnology company based in France that is developing T-specific immunotherapy treatments against invasive and metastatic cancers, is pleased to participate to BioPharm America 2015's convention which will take place in Boston from 15th to 17th September 2015 as part as a business trip organized by Medicen Paris Area's cluster.

« This convention is a good opportunity for OSE Pharma to have many contacts with pharmaceutical and biotechnology players in order to look for potential partnerships" adds Alexis Peyroles, Chief Financial Officer of OSE Pharma.

BioPharm America is the world's largest life sciences partnership's gathering organized by the EBD Group in collaboration with the Massachusetts Biotechnology Council (MassBio) in North America. It is a major conference on East Coast in the field of biotechnology and pharmaceutical industry.

Press Contacts

OSE Pharma sa
Dominique Costantini, CEO
dominique.costantini@osepharma.com
Mob +33 6 13 20 77 49

Alexis Peyroles, CFO
Alexis.peyroles@osepharma.com
Mob : +33 6 11 51 19 77

Citigate Dewe Rogerson
Laurence Bault / Lucie Larguier
+33 1 53 32 84 78
laurence.bault@citigate.fr

Alize RP
Florence Portejoie
+33 1 44 54 36 64 - + 33 6 47 38 90 04
fportejoie@alizerp.com

About OSE PHARMA

OSE Pharma is a European cancer immunotherapy company with a multi-epitope technology named Memopi® that directs the body's immune system to generate a specific cytotoxic T response to prevent cancer cell growth.

OSE Pharma's lead product, Tedopi®, combines 10 "neo-epitopes" directed against five tumour associated antigens. In its most advanced application it is about to enter a pivotal Phase 3 study in patients with advanced non-small cell lung cancer (NSCLC) who express HLA-A2 and who have failed first line therapy. Tedopi® has orphan drug status in the USA and is considered as personalised medicine in Europe in HLA-A2 positive patients.

Tedopi® could also be developed in a new Phase 2 clinical trial in combination with another immunotherapy treatment in NSCLC.
Tedopi® targets five tumour associated antigens (TAA), selected because their presence is linked to a poor prognosis and the severity of various cancers. Tedopi® contains a total of ten optimised epitopes, or "neo-epitopes", designed on the binding of HLA-A2 and TCR. These neo-epitopes generate strong specific T cytotoxic responses that fight cancer and prevent tumour escape. (ISIN: FR0012127173 ; Mnémo : OSE).

Follow us on Twitter @OSEPharma

Disclaimer:

This press release may expressly or implicitly contain forward-looking statements relating to OSE Pharma and its activity. Although OSE Pharma's management believes that the expectations reflected in these forward-looking statements are reasonable, investors are cautioned that such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from OSE Pharma's results, financial conditions, performance or achievements expressed, projected or implied by such information and forward-looking statements.

Other than as required by applicable law (article 223-1 *et seq* of the General Regulation of the AMF), OSE Pharma issues this press release at the date hereof and does not undertake any obligation to update or revise any forward-looking information or statements.

These risks and uncertainties include among other things, the uncertainties inherent in future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives,
For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Documents de Base filed with the AMF under number I. 14-056 on September, 17th 2014 and Chapter 2 "Risk Factors related to the Offer" in the prospectus approved by the AMF under number 15-078 on 6th March 2015, which can be found on the websites of the AMF (www.amf-france.org) and of OSE Pharma (www.osepharma.com).